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Abstract: Even if cancer stem cells (CSCs) represent only a small proportion of the tumor mass,
they significantly account for tumor maintenance, resistance to therapies, relapse and metastatic
spread, due to their increased capacity of self-renewal, multipotency, tumorigenicity and quiescence.
Emerging evidence suggests that the immune contexture within the tumor microenvironment (TME)
determines both the response to therapy and the clinical outcome. In this context, CSCs acquire
immune evasion skills by editing immune cell functions and sculpting the immunosuppressive
landscape of TME. Reciprocally, infiltrating immune cells influence CSCs self-renewal, tumorigenicity
and metastasis. In this review, we summarize the immunomodulatory properties of CSCs, as well
as the impact of innate immune cells on cancer cells stemness in the different phases of cancer
immunoediting process and neoplastic progression.




The transformation of normal cells into a malignant tumor is a multistep process through which
transforming cells acquire malignant features, described as “hallmarks of cancer”. These include
sustaining proliferative signaling, evading anti-proliferative safeguards, resisting apoptotic
programming, enabling replicative immortality, inducing angiogenesis, and activating invasion
and metastasis. Underlying these hallmarks are genome instability and smoldering inflammation,
which foster multiple functions of cancer cells [1]. Furthermore, new observations indicate that the
changes to which the transformed cells are subjected, including their heterogeneity and stemness,
are affected by and mutually influence the host’s immune-inflammatory response, suggesting a
model of tumor/host interdependence, in which the determinants of neoplastic progression are still
largely unclear.
1.2. Innate Immune Populations in Cancer
Solid tumors are composed not only of malignant cells, but are a complex network of
heterogeneous cell populations, including fibroblasts, endothelial cells and leukocytes, engaged
in reciprocal interactions guiding the construction of a permissive microenvironment for tumor growth.
This complexity creates a physical network, the tumor microenvironment (TME), which gradually
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reprograms immune and micro-physiological responses towards conditions that promote tumor growth
and metastasis [2,3].
Within this scenario, innate immune cells, i.e. macrophages (TAMs), neutrophils (TANs), dendritic
cells (DCs), myeloid-derived suppressor cells (MDSCs) and natural killer cells (NK), are the key
drivers of cancer-related inflammation and, due to their functional plasticity, can act decisive pro- or
anti-tumorigenic roles during different stages of neoplastic progression. In fact, innate immunity can
either block tumor development, by destroying tumor cells and/or inhibiting their growth, or support
proliferation and survival of transformed cells, by sculpting their immunogenicity and/or inhibiting
host’s protective anti-tumor responses [4–7].
This dynamic process has been conveyed in the “cancer immunoediting” hypothesis, encompassing
three key events: the “Elimination” phase that corresponds to cancer immunosurveillance, where mostly
tumor cells are detected and killed by components of the immune system; the “Equilibrium” phase,
in which a balance is established between immune and cancer cells; the “Escape” phase, in which
activation of immunosuppressive circuits allows immuno-evasion and spreading of cancer cells [8,9].
1.3. Cancer Stem Cells
It has been demonstrated that the rare tumor cells able to survive the elimination phase are
mostly cancer stem cells (CSCs) [10]. Even if their origin is not yet clear, the more trusted theory
defines CSCs as normal stem cells that have accumulated neoplastic mutations. Due to their ability to
develop into various cell types and support tissue regeneration, stem cells simultaneously became the
“holy grail” of regenerative medicine, and the “evil contender” of anticancer therapy. Indeed, CSCs
are considered responsible of tumor outgrowth, maintenance and progression, as well as resistance
to anticancer treatments [11]. Thanks to their ability to enter quiescence and to express multidrug
resistance extrusion pumps, CSCs survive conventional therapies (i.e., chemo and radio therapy) and
orchestrate the metastatic spread to distant tissues. Identified for the first time in 1997 by Dick and
Bonnet in leukemia [12], to date, CSCs have been described in almost all neoplastic tissues. Even if
a universal marker for their identification is lacking, according to the tissue of origin, CSCs can be
isolated on the base of the expression of specific surface markers, such as CD133, ALDH, c-kit [13]
and CD44/CD24, as well as stemness-associated master gene regulators (e.g., Nanog, Sox2 and Oct4).
In addition, CSCs are characterized by the capability to perpetuate themselves (self-renewal) and/or
differentiate into all the different cell subsets of the originating tissue, together with the ability to grow
in vitro as rounded structures called spheroids, resembling the 3D structure of the tumor mass [14].
Thanks to these double skills, CSCs maintain a stem reservoir and, simultaneously, sustain tumor
growth. The balance between self-renewal and differentiation is controlled by the niche, a well-defined
location where CSCs reside. Through the activation of specific pathways (i.e., Notch, Wnt/ß catenin
and Sonic Hedgehog), the niche regulates the proliferative status of CSCs in response to cell-to-cell
contacts and soluble factors released from other components of the TME. Accumulating evidences
indicate that the interplay between innate immune components and CSCs in the different phases of
cancer development acts as a key determinant of TME (Figure 1).
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Figure 1. Cross-talks between cancer stem cells and innate immunity cellular components in the 
different phases of neoplastic progression. Schematic representation of the cross-talks between 
immune cells and cancer stem cells (CSCs). In the elimination phase, the different components of the 
innate immunity attack tumor mass but fail to eradicate CSCs, thanks to their ability to enter 
quiescence, activate anti-apoptotic pathways (overexpression of Bcl2/Bcl-x and Survivin), “don’t eat 
me” signal (CD47), and down-regulate the expression of tumor-associated antigens (TAAs), human 
leukocyte antigen (HLA) as well as ligands for natural killer cell (NK)-mediated recognition. Once 
survived this step, CSCs propagate themselves (self-renewal) and edit the immune system through 
the release of cytokines and soluble factors (IL-4, IL-13, G-CSF and CCL2/15) that activate the bone 
marrow (BM) towards an emergency myelopoiesis, characterized by expansion of myeloid 
suppressor cells. Thus, CSCs create a ‘permissive immunosuppressive tumor microenvironment’ 
(escape phase) that permits them to proliferate and differentiate, leading to tumor relapse. As the 
tumor grows, some CSCs lose their epithelial phenotype (reduced expression of E-cadherin) and 
acquire mesenchymal properties (i.e., increased expression of Vimentin, Fibronectin, Snail, Slug and 
Twist), through the epithelial to mesenchymal transition process (EMT), and leave the tumor site to 
enter the blood stream. In the meantime, the ongoing cancer-related inflammation produces cytokines 
and chemokines that promote accumulation of myeloid-derived suppressor cell (MDSCs), Treg, NKs 
and tumor-associated macrophages (TAMs) in distant tissues (i.e., lungs) to create pre-metastatic 
niches, where circulating CSCs will home and generate metastatic foci. (DC, Dendritic cell). 
2. Elimination of Tumor Bulk 
Microbial infections, autoimmunity and immune deregulation may instate chronic 
inflammatory conditions, which determine increased susceptibility to cancer development [2,15]. 
According to this causal association, obesity-associated inflammation and inflammaging are 
characterized by an increased risk of tumor development [16]. Metabolic and inflammatory disorders 
typical of obese people correlate with body–mass index (BMI) and increased DNA lesions [17], as 
well as with cancer growth, by favoring cancer cell proliferation, migration and resistance to 
apoptosis [18]. Further, the inflammatory connection postulated between aging and cancer appears 
to support changes in chromatin functions, reductions in autophagy capacity, and dysbiosis, which 
concur to create a pro-tumorigenic environment [18]. 
Figure 1. Cross-talks between cancer stem cells and innate immunity cellular components in the different
phases of neoplastic progression. Schematic representation of the cross-talks between immune cells and
cancer stem cells (CSCs). In the elimination phase, the different components of the innate immunity attack
tumor mass but fail to eradicate CSC , thanks to th ir ability to enter quiescenc , activate anti-apoptotic
pathways (overexpression of Bcl2/Bcl-x and Sur ivin), “don’t eat me” signal (CD47), and own-regulate
the expression of tumor-associated antigens (TAAs), human leukocyte antigen (HLA) as well as
ligands for natural killer cell (NK)-mediated recognition. Once survived this step, CSCs propagate
themselves (self-renewal) and edit the immune system through the release of cytokines and soluble
factors (IL-4, IL-13, G-CSF and CCL2/15) that activate the bone marrow (BM) towards an emergency
myelopoiesis, characterized by expansion of myeloid suppressor cells. Thus, CSCs create a ‘permissive
immunosuppressive tumor microenvironment’ (escape phase) that permits them to proliferate and
differentiate, leading to tumor relapse. As the tumor grows, some CSCs lose their epithelial phenotype
(reduced expression of E-cadherin) and acquire mesenchymal properties (i.e., increased expression of
Vimentin, Fibronectin, Snail, Slug and Twist), through the epithelial to mesenchymal transition process
(EMT), and leave th tumor site to enter blo d stream. In the me ntime, the ngoing cancer-related
infl mmation produces cyt kines and chemokines that promote accumulation of my loid-derived
suppressor cell (MDSCs), Treg, NKs and tumor-associated macrophages (TAMs) in distant tissues (i.e.,
lungs) to create pre-metastatic niches, where circulating CSCs will home and generate metastatic foci.
(DC, Dendritic cell).
2. Elimination of Tumor Bulk
Microbial infections, autoimmunity and immune deregulation may instate chronic inflammatory
conditions, which determine increased susceptibility to cancer development [2,15]. According to
this causal association, obesity-associated inflammation and inflammaging are characterized by an
increased risk of tumor development [16]. Metabolic and inflammatory disorders typical of obese
people correlate with body–mass index (BMI) and increased DNA lesions [17], as well as with cancer
growth, by favoring cancer cell proliferation, migration and resistance to apoptosis [18]. Further,
the inflammatory connecti n postulated between aging and cancer appears to support changes in
chromatin functions, reductions in autophagy capacity, and dysbiosis, which concur to create a
pro-tumorigenic environment [18].
A major challenge is to understand how these conditions predisposing to tumor development
intersect with the immune and inflammatory responses, and how the nascent tumor reprograms the
immune system, gradually disarming its anti-tumor potential.
Int. J. Mol. Sci. 2020, 21, 3352 4 of 22
During the early stages of tumor development (elimination phase), immune cells retain their
immunosurveillance properties, and anti-tumor immunity prevails. In cooperation with adaptive
immunity (T and B lymphocytes), innate immune cells (macrophages, neutrophils, DCs and NK) provide
a robust first line of defense against cancer cells, detecting and eliminating the more immunogenic
cancer cells and counteracting spontaneous tumor growth [9,19]. NK cells possess potent cytolytic
activity, to rapidly kill virally-infected or malignantly transformed cells in a manner unrestricted
to the major histocompatibility complex class I (MHC-I), and secrete various effector cytokines and
chemokines, like IFNγ, tumor necrosis factor alpha (TNFα), GM-CSF, CCL5 and IL-22, involved
in the recruitment and activation of DCs and TAMs [20,21]. The activation of NK cells relies on
the integration of signals derived from an array of cell surfaces activating (CD16 and NKG2D),
natural cytotoxicity-mediating receptors (NKp30, NKp44, and NKp46) and inhibitory receptors (KIR,
CD94/NKG2A and CD300a) [22–24].
TME-targeted, NK-mediated responses are triggered via: i) binding of the NKG2D to its ligands
(stress-inducible MHC-Ib molecules, DNA damage responses); ii) binding of NKp30 and NKp44 with
their respective ligands; and iii) antibody-dependent cellular cytotoxicity (ADCC), where the CD16 Fc
receptor on NK cells binds to cell-bound antibodies [25,26]. In all cases, upon conjugations with target
cells, NK cells release cytotoxic and proteolytic granules containing perforin and granzymes, for target
cell lysis [27], and/or inducing target cell apoptosis via TNFα, Fas ligand (FasL), and TNF-related
apoptosis-inducing ligand (TRAIL) [28,29].
In addition to their direct role in tumor surveillance, NK cells contribute to the formation of an
efficient anti-tumor microenvironment through the early and rapid production of anti-tumor effector
cytokines, such as IFNγ, which act in a paracrine manner on the other immune components of the
TME. IFNγ reprograms TAMs into a tumoricidal (M1) phenotype [30,31], and promotes anti-tumor
T-cell responses, inducing tumor-specific T cell memory [32], facilitating the differentiation of Th1
cells, and inhibiting the expression of exhaustion marker PD-1 on CD8+T cells [33]. Additionally,
the cytokine-mediated (i.e., IFNγ and TNFα) interplay between NK cells, effector T cells and TAMs
boosts differentiation of cytotoxic T cells (CTLs), enhances macrophage phagocytosis and the cytotoxic
ability of NK cells, and increases the recruitment of cytotoxic TANs [34,35]. Moreover, in several
mouse models, it has been shown that NK cells are required for the accumulation of conventional
type I dendritic cells (cDC1) in TME. In fact, cDC1 are recalled through the secretion of CCL5
and XCL1 chemoattractants, resulting in increased priming and activation of anti-tumor T cells,
and stimulating the overall effector immune response [36]. DCs represent not only the most important
antigen-presenting cells (APCs), but also the link between innate and adaptive immunity, playing a
key role in the priming and consolidation of anti-tumor adaptive immune response [37]. The ingested
tumor-derived material is processed into peptides by immature DCs, and presented to T lymphocytes
on MHC-I or MHC-II molecules. To efficiently drive the clonal proliferation and activation of CD4+ T
helper (Th) or CD8+ CTL cells, DCs need to express co-stimulatory molecules, such as CD80, CD86,
CD40, OX40L, or ICOSL, and produce stimulatory inflammatory cytokines (i.e., IL-6, IL-12, IL-23 and
TNFα). In turn, DCs and T helper cells support the activation of NK, NKT and macrophages [38,39].
Activated macrophages can exhibit both proinflammatory (“M1 type”, driven by
lipopolysaccharide (LPS) and IFNγ) or anti-inflammatory (“M2 type”, driven by IL-4 and IL-13)
phenotype. The macrophage polarization status can be dynamically reprogramed during tumor
development [40]. In the early steps of tumorigenesis, TAMs display M1 polarization state and play
a relevant role in the elimination of immunogenic cancer cells, and in restraining tumor growth,
through the expression of high levels of reactive nitrogen and oxygen intermediates and the secretion
of pro-inflammatory and immune-stimulatory cytokines, such as IL-12, IL-6, IL-1, IL-23, CXCL19 and
CXCL10. Then, these cytokines stimulate the development of Th1, Th17, NK and NKT cells [41,42].
In addition, macrophages could contribute to the elimination of nascent tumor cells through the release
of nitric oxide (NO) and TNFα, which can be induced through NK2GD triggering [43]. Other stimuli,
such as IFNγ, and anti-CD40 and toll-like receptor (TLR) ligands, can induce the release of NO and
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TNFα, thereby stimulating tumoricidal activity of macrophages [44]. Thus, a high M1/M2 ratio is
predominantly associated with improved survival in multiple cancers [45,46].
Similar to the M1/M2 phenotype of TAMs, it has been proposed that tumor-associated neutrophils
(TANs) can be polarized toward anti-tumor N1 or pro-tumorigenic N2 phenotype. During the first
steps of tumorigenesis, the recruitment of TANs to the TME is mediated by CXCR2 ligands, such as
CXCL1, CXCL2 and CXCL5, secreted by cancer and stromal cells. Once within TME, the presence
of type-1 IFNs shapes their phenotype towards an anti-tumor N1 polarization state, associated with
increased tumor cytotoxicity, high neutrophil extracellular traps (NETs) expression, and enhanced
TNFα and reactive oxygen intermediates expression [47,48]. However, despite the fact that during the
early phase of cancer development a vigorous immune attack contributes to the elimination of cancer
cells, simultaneously it also selects the less immunogenic variants, invisible to immune detection,
such as the CSCs. The low immunogenicity features and the quiescent behavior exhibited by CSCs,
which allow their immune escape, are described below (see also Figure 2).
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Figure 2. Mechanisms of CSCs immune escape. The figure summarizes the CSC features and
CSCs-mediated immunosuppressive events during neoplastic progression. It must be taken into
account that while the precise kinetics of the immunosuppressive events utilized by CSCs remains
doubtful, it is possible to postulate that the activation of part of these mechanisms occurs in the very
early stages of tumor development, when instead the non-CSCs are effectively eliminated by the
immune response. These immunosuppressive mechanisms are likely to remain active, allowing the
disease recurrence. CSCs overexpress PD1 ligand (PDL1) or down-regulate NKG2D ligand (NKG2DL)
to respectively inhibit T and NK cells’ antitumor functions. To maintain a low immunogenic profile,
CSCs down-regulate the expression of MHC class I and II, thus impairing TCR-mediated recognition,
and express the “don’t eat me” signal (CD47), which inhibits the phagocytic activity of SIRP1α+
macrophages. At the same time, expression of Fas ligand (Fas L) by CSCs induces apoptosis of effector
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T cells. In addition, CSCs express multi drug resistant pumps (e.g., MDR1 and ABCG2) and activate
pathways (e.g., Notch, Wnt/β-catenin and Sonic Hedgehog) to survive anti-neoplastic treatments and
enter quiescence. In support of tumor growth, CSCs gradually create a tumor-promoting environment,
by releasing cytokines and soluble factors that affect the polarization of TAMs towards an M2 protumor
phenotype, and favoring expansion of myeloid-derived suppressor cells (MDSCs). In addition, CSCs
release exosomes endowed with several effects, according to their cargo. Exosomes impair dendritic
cell (DC) maturation, modulate the inflammatory response of tumor-associated macrophages (TAMs)
and promote neoangiogenesis. The formation of new vessels is fostered also by vascular endothelial
growth factor (VEGF), released directly by CSCs, that in concert with other cytokines and soluble
factors orchestrates the creation of a prone premetastatic niche. At the same time, Treg are recruited
into the premetastatic niche, and the cancer associated fibroblasts (CAFs) are functionally shaped to
remodel extracellular matrix and to sustain CSC migration and tumor progression. During this last
phase, CSCs respond to the increased HIF-1α levels, activating epithelial to mesenchymal transition
(EMT) leading to the acquisition of mesenchymal features (e.g., expression of Snail. Zeb1/2, and Twist).
2.1. Equilibrium and Survival of CSCs
The ability of poorly immunogenic CSCs to persist in a dormant state provides a rationale for
both their immuno-evasion and resistance to anticancer therapies. In fact, in response to different
signals, CSCs can exit the cell cycle and enter quiescence, a G0 cell cycle arrest status that is mainly
controlled by the transcription factor homeobox protein nanog (NANOG) through the Wnt/β catenin
pathway [49]. Furthermore, compared to bulk tumor cells, CSCs exhibit increased DNA repair
and reduced apoptosis [50,51], along with enhanced expression of drug efflux pumps, such as
ABCG2 and MDR1, which makes them inherently drug resistant [52] and strengthens their stemness
properties [53,54].
CSCs exhibit various properties to directly evade effector mechanisms of immune cells (Figure 2).
Among all, CSCs down-regulate the expression of MHC class I and II molecules. A comparison
study between CSCs, grown as spheroids, and non-stem cancer cells (non-CSCs) isolated from
glioblastoma [55] and melanoma [56], demonstrated that CSCs are characterized by weak or
no expression of MHC class I molecules, suggesting an impaired recognition by CD8+ T cells.
In agreement, phenotypic analysis of CSCs, isolated from primary colorectal carcinoma specimens and
co-cultured with peripheral blood mononuclear cell (PBMC), demonstrated their weak immunogenicity,
paralleled by low expression of class I and II human leukocyte antigen (HLA) and high levels of
immunomodulating cytokines, such as IL-4 [57].
In a study on tumor relapse in head and neck squamous cell carcinoma, it has been demonstrated
that first line radiotherapy treatment is associated with an enrichment of tumor cells characterized
by defective antigen processing machinery (APM) and low expression of HLA class I molecule [58],
that correlated with a reduction in the patient’s overall survival. Down-regulated or defective APM (i.e.,
transporter associated antigen processing proteins TAP or ß-microglobulin) has been also demonstrated
in CSCs [59], and correlated with the absence or suboptimal expression of tumor-associated antigens
(TAAs) [60]. In line with this, reduced expression of HLA I or TAP molecules was reported in CSCs
isolated from melanoma [56], lung cancer [61], head and neck squamous cell carcinoma (HNSCC) [58]
and colorectal cancer [57], in comparison to the non-CSCs counterparts.
Within the framework of an extreme capacity for immune-evasion and survival, high levels of
CD200, FasL, and anti-apoptotic proteins like Bcl-2, Bcl-xL, or Survivin, were shown to protect CSCs
against chemotherapeutic drugs, and increase resistance toward apoptosis-inducing immune effectors
like T or NK cells [62,63].
More recently, a link between death receptor CD95/Fas, type I interferons (IFN-I)-dependent
activation of STAT1, and stemness, has been described in different cancer types [64]. In fact, chronic
stimulation of CD95 in tumor cells has been reported to activate the IFN-I pathway and result in
increased expression of stem-like markers in breast cancer, glioblastoma and squamous carcinoma [65].
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CSCs are also able to convert a subset of immature DCs into TGF-β-secreted cells, thus driving
expansion of regulatory T cells (Treg) in lymphoid organs [66].
Next to resisting T cell-mediated eradication, CSCs also escape NK anti-tumor activity. Several
works demonstrated that CSCs down-regulate NK-activating NKG2D ligands, thus impairing their
innate immune response against tumors [55,67]. Additionally, CSCs express low levels of ligands for
the NK cell activator receptor NKp44, and no ligands for NKp30, NKp46 and CD16, while increasing
inhibitory NK cell receptors ligands [10,68]. Thus, as demonstrated by Reim et al., CD44high/CD24low
breast CSCs selectively escape from NK cell-mediated killing and Trastuzumab-dependent ADCC [69].
Moreover, in several types of malignancies, including lung, pancreatic and hepatocellular carcinoma,
CSCs, compared to non-CSCs, were reported to express increased levels of the “don’t eat me” signal
CD47, thus preventing their phagocytosis by signal regulatory protein α (SIRPα) on TAMs [70–72].
In line with this, studies showed an increased phagocytosis of CSCs by macrophages upon blocking of
CD47 [70,73].
However, some reports showed similar HLA expression or higher new antigen expression in
CSCs, as compared to the non-CSCs counterpart, suggesting that CSCs also present immunogenic
potential, able to activate T-cell mediated anti-tumor responses [74]. A study on colon cancer showed
no differences in HLA class I expression between CSCs and non-CSCs [75]. Similarly, Chikamatsu
et al. did not identify differences in HLA class I and TAP expression in CSCs vs non-CSCs in head
and neck squamous cell carcinoma (HNSCC), although CSCs displayed reduced levels of TAP2.
Conflicting results were obtained on NK-mediated recognition and elimination of CSCs [76]. By using
several cancer cell lines and primary samples, Ames et al. demonstrated that the CSCs (identified as
CD24+/CD44+/CD133+/ALDHbright) present higher levels of MICA/MICB, Fas and DR5, NK activator
ligands, as compared to non-CSCs [77].
The contrasting evidences present in the literature could be partially due to lack of universal
markers for CSCs identification in the different tissues, and different non-standardized techniques
used for their isolation and culture [74].
2.2. CSCs Awakening and Immunoediting
CSCs survive tumor eradication in a state of tumor dormancy, without losing their malignant
potential, by orchestrating the shift from a state of immunosurveillance/equilibrium to an escape phase
(Figure 2).
The lack of favorable microenvironmental conditions and specific stimuli for cell proliferation
maintain CSCs in quiescence, preventing the formation of a tumor mass [60]. In primary samples of
acute myeloid leukemia, Shapiro’s group demonstrated that leukemia cells collected at tumor relapse
had undergone a lower number of divisions, compare to cells collected at diagnosis, and presented
features resembling the stem cell subset [78]. These results indicate that tumor growth is triggered by
an aggressive and slowly dividing cancer cell clone, the CSCs, endowed with tolerogenic properties.
During the escape phase, CSCs secrete cytokines, chemokines and soluble factors that activate
different pathways, aiming at tipping the balance towards immune tolerance, in order to suppress and
edit the immune system and create a pro-tumoral niche [79]. In concert with Treg, TAMs and MDSCs
represent the major orchestrators of this process, as they boost an immune-tolerant TME through the
secretion of immunosuppressive molecules, such as IL-10, TGF-β and prostaglandins [80]. In addition,
they inhibit the secretion of IL-12 by DCs, blocking effective Th1 response and excluding NK, NKT and
effector T cells [81–84]. The immunosuppressive evolution of TME, driven by immunosuppressive
factors and cytokines (i.e., TGF-β ), subsequently induces a population of pro-angiogenic, N2-polarized
TANs [47].
TAMs and MDSCs abundantly expand in tumor bearers as a result of an “emergency
myelopoiesis”, which leads to pathological expansion of tumor-promoting myeloid cells, endowed
with tumor-promoting activities [85,86]. Similarly, with infections [87,88], emergency myelopoiesis
occurring in cancer is an attempt to ensure proper supply of immune cells for the increased demand [86].
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Nevertheless, in addition to the local editing of immune cells occurring in the TME, cancers deliver
systemic immunological stresses that alter the differentiation of bone marrow progenitors, hence
affecting magnitude, composition and specialized functions of the hematopoietic output [89,90].
Subsequently, tumor-infiltrating myeloid cells, mobilized from the bone marrow to the periphery,
are recruited to the tumor site, where they encounter extreme microphysiological conditions (i.e.,
hypoxia, low glucose levels, low pH and inflammatory signals) that further boost their reprograming
towards a tumor-promoting phenotype [84,91]. CSCs participate in shaping myeloid cell phenotype
by releasing inflammatory mediators, such as IL-10 and IL-13, that promote the differentiation of
immature myeloid cells [74]. In addition, CSCs-derived G-CSF, CCL2, CCL15 and CXCL12 recruit
MDSCs into the TME [92,93]. In a mouse model of pancreatic cancer (PC), it has been demonstrated that
monocytic-MDSCs (M-MDSCs), identified as CD11b+/Gr1+/Ly6G-/Ly6Chigh, stimulate the expansion
of ALDHbrigh CSCs, and increase the expression of genes associated with the EMT process [94].
Similar results were obtained analyzing primary samples of M-MDSCs isolated from peripheral
blood of PC-bearing patients. M-MDSCs increase the percentage of CSCs and promote acquisition
of mesenchymal features. Interestingly, the authors proved that the CSCs stimulation was mediated
by the activation of the STAT3 pathway, and that the blockade of STAT3 activation restored the basal
levels of ALDHbrigh CSCs [94]. Wang et al. reported also that granulocytic-MDSCs (G-MDSCs)
enhance colorectal cancer (CRC) cell stemness via exosomes and exosomal S100A9 in the tumor
microenvironment, especially under hypoxic conditions. In line with this, plasma exosomal S100A9 in
CRC patients is markedly higher than that in healthy subjects [95].
It was also reported that MDSCs induce the expression of microRNA101 in ovarian cancer cells,
which subsequently repress the corepressor gene C-terminal binding protein-2 (CtBP2), increasing their
stemness and tumorigenic potential [96]. Additionally, prostaglandin E2 (PGE2), secreted by MDSCs,
boosted the stemness of cervical cancer cells [97], while MDSCs enhanced stemness-properties of breast
tumor cells through the secretion of IL-6 and nitric oxide (NO), in a STAT3-dependent manner [98].
In line with this, the STAT3/IL-6 pathway was reported to be involved in the increased frequency
of CD44+ hepatocellular carcinoma (HCC) stem cells, when co-cultured with TAMs isolated from
HCC-bearing patients. As demonstrated by Wan and colleagues, disruption of this axis, through STAT3
or IL-6 inhibitors, resulted in the impairment of the CSCs’ expansion, both in vivo and in vitro [99].
These results support the idea that TAMs contribute to neoplastic progression also by nurturing the
cancer stem cell niche [100,101].
An existing mutual crosstalk indicates that TAMs release cytokines that contribute to the activation
of CSCs, which in turn release factors contributing to switching TAMs toward an M2-polarized
and tumor-promoting phenotype [81]. In this scenario, periostin, a secreted extracellular matrix
protein produced by glioma stem cells, was shown to attract M2 TAMs, hence promoting tumor
growth [102]. Colony-stimulating factor 1 (CSF-1) and CCL2, enriched in CSC niches, mediated
the recruitment of TAMs and shifted the polarization of the monocyte pool toward M2-activation
state [103]. As demonstrated in ovarian cancer [104] and glioma [105], CSCs release cycloxygenase2
and CCL2, as well as CSFs and TGF-β, to orchestrate the polarization of TAMs [106].
Interestingly, pancreatic ductal adenocarcinoma (PDAC) cells polarize TAMs toward an M2
phenotype, which in turn actively secrete high levels of ISG15, an interferon-stimulated gene which
promotes self-renewal, tumorigenic, chemoresistant and migratory capacities of PDAC CSCs in vivo
and in vitro [107,108].
Reciprocally, TAMs play a key role in maintaining the CSCs’ functions [109]. In non-small-cell lung
cancer (NSCLC) and HCC, IL-6 produced by TAMs supported the expansion and drug resistance of
CSCs in a STA3-dependent manner [99,100]. In addition, M2 TAMs promoted invasion and proliferation
of CSCs by the secretion of TGF-β in HCC, along with the release of PDGF, IL-8 and CXCL12 [110,111].
VEGF, which is produced not only by M2 TAMs but also by CSCs themselves, promotes angiogenesis,
tumorigenicity and stem-like phenotypes of CSC themselves [112,113]. TAM-initiated Wnt signaling
Int. J. Mol. Sci. 2020, 21, 3352 9 of 22
activation, during CSCs/TAM interaction, constitutes a positive feedback loop that contributes to the
maintenance of stemness of ovarian CSCs [114].
Besides the paracrine interaction via soluble molecules, TAMs interact with CSCs also in a cell–cell
contact dependent manner; in particular, the ligation of CD90 to Ephrin type-A receptor 4 (EphA4),
expressed on the surface of CSCs, induces the production of IL-6, IL-18 and GM-CSF, which in turn
sustain stem cell-like niche [115].
Additionally, much evidence in the literature highlights the CSCs-exosome role in creating a
permissive pro-tumoral microenvironment. In this regard, it was reported that glioblastoma stem
cell-derived exosomes skew monocytes toward an immunosuppressive M2 phenotype, through the
STAT3 pathway, fostering PD-L1 expression and cytokines production, such as MCP-3 and CXCl1,
which further enhance the recruitment of myeloid cells into TME. [116]. Similarly, Domenis et al.
showed that peripheral blood monocytes, from healthy donors, exposed to glioma stem cell-derived
exosomes had increased IL-10 and Arg1, and downregulated class II HLA (HLA-DR) expression,
thus inducing cells with characteristics similar to M-MDSC [117]. In line with this, TGF-β, as well as C1q-
and semaphorins-containing exosomes secreted by human and mouse tumor-educated mesenchymal
stem cells, drive accelerated breast-cancer progression by inducing differentiation of M-MDSCs into
immunosuppressive PDL-1+CD206+Arg1+IL-10+ M2-polarized macrophages [118]. In a renal cancer
model, CSCs impaired DCs maturation and T cell immune response, fostering tumor immune-escape,
through the release of HLA-G-carrying extracellular vesicles [119]. Moreover, mesenchymal stem
cells-derived exosomes contribute to modulating the inflammatory responses of TAMs, inducing higher
expression of anti-inflammatory IL-10 and TGF-β transcripts and reducing levels of pro-inflammatory
IL-1β, IL-6, TNFα and IL12p40 [120].
Colorectal cancer stem cell-derived exosomes prolonged the survival of bone marrow-derived
neutrophils, and induced a pro-tumoral phenotype in TANs, by increasing IL-1β expression [121].
In rat models of HCC, hepatic CSCs-derived exosomes displayed protumor functions, influencing
apoptosis, angiogenesis, metastasis and invasiveness, as well as EMT of tumor cells, via altering
the expression of targeted molecules, such as p53, Bcl2, VEGF, TGF-β and matrix metalloproteinase
(MMP)-9 [122]. Sun et al. recently reported that glioma stem cell-derived exosomes promoted
angiogenesis by containing high levels of miRNA-21, which in turn up-regulates VEGF [123].
The extracellular CSC-derived vesicles in human renal cell carcinoma have been shown to contain
several proangiogenic mRNAs, such as VEGF, angiopoietin1, MMP-2 and MMP-9, thereby modifying
the TME by triggering angiogenesis and promoting the formation of premetastatic niches [124].
In line with this, CSC-derived exosomes induced metastasis by promoting EMT in renal cell
carcinoma [125] and thyroid cancer, via the transfer of miRNA-19b-3p and non-coding-RNAs,
respectively [126].
2.3. Dissemination and Metastases
The last phase of the neoplastic progression is tumor metastatization, the spread of tumor cells
from the primary site to non-adjacent tissues, where they give rise to a tumor mass resembling the
primary tumor. Metastases is the major cause of cancer-related death, accounting for almost 90% of the
cases. During the metastatization process, tumor cells acquire the capability to degrade the extracellular
matrix, leave the tumor site, penetrate into the blood vessels (intravasation) and exit in distant tissues
(extravasation), where they conclude the metastatic colonization. Strikingly, primary tumor-derived
factors actively condition the nutrients, extracellular matrix and immune cell environment of a distant
organ, to make it accessible to metastatic seeding [127]. Thus, the pre-metastatic niche can be primed
and established through a dynamic interplay among tumor-derived factors, tumor-mobilized bone
marrow-derived cells, and local stromal components [128].
Stephen Paget in 1889 proposed the “seeds and soil” theory, according to which metastatization
occurs only when designated tumor cells reach specific tissues already activated to promote tumor
cell growth and survival [129]. To date, it is clear that CSCs are the designated tumor cells, since they
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possess the capability to survive sufficiently in the blood stream, and subsequently to colonize distant
tissues. Here, CSCs can remain dormant for a long time, to then restart proliferation and differentiation,
thus recapitulating the primary tumor phenotype. To acquire migratory ability, CSCs undergo the
EMT [130]. EMT is a program that in non-pathological tissues occurs during embryonic developments;
in neoplastic tissues, instead, it sustains tumor cell dissemination to distant organs [131]. During EMT,
CSCs lose their polarity and cell-to-cell junctions, acquiring a spindle shape and mesenchymal features,
such as motility and invasiveness. Indeed, hallmarks of EMT are down-regulations of epithelial
markers (i.e., E-cadherin) and up-regulations of mesenchymal ones (i.e., Vimentin, Fibronectin and
V-cadherin) [132].
In the tumor context, activation of EMT can be triggered by several factors (i.e., hypoxia, nutrient
deprivation and starvation), and pathways including NF-κB, Notch, and Wnt/β catenin, as well as
TGF-β. Indeed, different from the stage of tumor onset, in the later stage of neoplastic progression,
TGF-β orchestrates CSCs’ metastatic spread through the activation of Smad proteins, which in turn
regulate the expression of target genes, such as master transcription factors Snail, Zeb1, Zeb2 and
Twist, that drive the EMT program [133–135].
CSCs can directly produce TGF-β, which acts in an autocrine manner, to sustain their own
metastatic potential, or affect adjacent/distant cells [136]. Tumor-derived TGF-β, together with other
factors, such as VEGFA and TNFα, stimulates the release of chemoattractants, such as S100A8 and
S100A9, that mediate the recruitment of immune cells in the pre-metastatic niche [137]. Indeed,
as foreseen by Paget [129], in the metastatic process a prone niche is fundamental for tumor cell
seeding and tissue colonization. In accordance with this, Sceneay J et al. demonstrated that primary
tumor hypoxia induces tumor cells to release CCL2, G-MCSF, TNFα, VEGF, TIMP-1 and MMP-9,
which orchestrate the recruitment of MDSCs (CD11b+/Ly6Cmed/Ly6G+) in the pre-metastatic lung
niche [138]. Among all these, tumor-derived CCL2 stimulates the accumulation of myeloid cells
and controls the differentiation of MDSCs into immunosuppressive macrophages, which in turn
enhance metastases formation (e.g., CSCs establishment, proliferation and differentiation). In addition,
hypoxia-induced tumor-released factors recall Treg and NK cells in the premetastatic niche [139].
However, once in situ, NK cells present an impaired differentiation status and reduced cytotoxic
potential [138], thus creating an immunosuppressive environment favoring the settling down of CSCs
and the growth of metastases [140]. Preclinical evidence in both Lewis lung cancer (LLC) and melanoma
(B16) mouse models [141] reported that VEGFR1-expressing, bone marrow-derived hematopoietic
progenitors accumulate in the pre-metastatic sites, before the detection of metastatic cells.
Moreover, additional immune cells are involved in the promotion of the metastatic process. TAMs,
for instance, regulate stroma invasion and intravasation of tumor cells. In response to CSF1 (secreted
by tumor cells), TAMs release the epidermal growth factor (EFG) that binds its receptor on the surface
of tumor cells, activating signaling of motility, matrix degradation and invasion of the surrounding
tissue [142]. In addition, TAMs secrete CCL18 [143] and SPARC [144], which enhance the adhesive
capability of tumor cells to the extracellular matrix, helping CSCs to enter blood vessels and migrate to
the metastatic niche. On the other side, tumor-released VEGFA, semaphorin 3A and CXCL12 recruit
TAMs in pre metastatic niches, where they suppress the cytotoxic activity of CD8+ T cells and promote
recruitment of Treg cells [145]. DCs, as well, participate to the creation of an immunosuppresive niche,
inducing the expansion of Treg and the inhibition of CD8+ T cells, as demonstrated in liver metastasis
from pancreatic cancer cells [146].
De Visser and colleagues, instead, recently demonstrated in a model of mouse breast cancer
that neutrophils create a prone metastatic niche for tumor circulating cells. The authors showed that
neutrophils release nitric oxide (NO) to suppress CD8+ T cells, allowing the growth of metastatic
foci. Neutrophil depletion, using anti-Ly6G antibody, did not affect primary tumor growth, but was
associated with a reduction in lung and lymph node metastasis [147]. More recently, the same authors
demonstrated that a mechanistic link between the loss of p53 in cancer cells, secretion of Wnt ligands
and systemic neutrophilia potentiates metastatic progression [148]. Further, in support of an active
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role of neutrophils in cancer cells spreading, Wculek et al. proved that neutrophil-derived leukotrienes
orchestrate lung metastatization of breast cancer, by enhancing the proliferation of high tumorigenic
CSCs [149].
Some evidence leads to speculation that soluble factors, exosomes and extracellular vesicles,
not only from CSCs but also from the microenvironment of the primary tumor, could promote,
at least in part, the construction of premetastatic niches, by modulating the differentiation of the
cellular components of TME [150,151]. It is known that CSCs modulate stromal activity; for example,
transforming fibroblasts into cancer-associated fibroblasts (CAFs) through cytokine secretion (i.e.,
TGF-β) [152]. As a consequence, CAFs release other cytokines, chemokines, growth factors and matrix
metalloproteinases (i.e., TGF-β, PGE2, CXCL12, VEGF, MMPs, etc.) that sustain tumor progression,
EMT transition and cancer stemness [153–155]. In turn, CAFs-derived exosomes contribute to the
conversion of cancer cells into CSCs, for example, via activation of Wnt and NOTCH signaling
pathways, and support the self-renewal and stemness properties of existing CSCs [156,157]. Recently,
Su S. et al. demonstrated that a subset of CD10- and GPR77-expressing CAFs promote tumor
formation and chemoresistance, by favoring the formation of a CSCs niche [158]. Accordingly,
Donnarumma et al. identified three miRNAs (miR-21, -378e and -143), enriched in exosomes derived
from CAFs, which could significantly increase the ability to promote stemness and EMT phenotype of
breast cancer cells [159]. Furthermore, CAFs secreted exosomes fostering breast cancer cell migration
through Wnt-planar cell polarity (PCP) signaling [160]. Such interactions may create a niche for
tumor growth and metastasis [161]. As the niche is established, CSCs recruit TAMs, CAFs and other
stromal cells, to establish the paracrine loops that supply CSCs with TNFα and TGF-β for CSC
maintenance [111,140,162]. In the meantime, the surrounding CAFs secrete MMPs and cathepsins to
further break down the extracellular matrix, which in turn releases TGF-β and various growth factors
like VEGF-A, hence allowing tumor expansion [163].
3. Immunological Targeting of CSCs
As discussed, CSCs are able to shape the TME by attracting immunosuppressive innate cell
subsets and inhibiting effector T cells. On the other hand, stromal cells and infiltrating immune cells
support CSCs’ self-renewal, tumorigenicity and metastasis [74]. Additionally, CSCs resist conventional
cancer therapies, primarily due to their high capability to repair DNA damage and to proliferate
slowly [11,105,164]. Radiation is commonly used to treat many types of cancer, and its combination
with immunotherapy is considered promising [165]. This combination is expected to have synergistic
effects, stemming from both local and systemic tumor control, due to the unique and intriguing
interactions between radiation and the immune system [166]. Interestingly, radiotherapy induces
pro-inflammatory cytokines in TME (i.e., IL-1β, TNFα, TGF-β, CXCL12, IL-6, MMPs, etc.) [167],
which lead to the up-regulation of reactive oxygen species (ROS) scavengers in CSCs and the activation
of downstream STAT3 signaling, with development of highly invasive CSCs phenotypes [168,169].
These results highlight the need for new strategies that may selectively target the CSCs, highlighting
their therapeutic potential combined with conventional antineoplastic therapy [170].
Combination immunotherapies would be an ideal approach to restore anti-tumor immunity
against CSCs. As mentioned, active STAT3 signaling plays an important role in CSCs/immune cells
interaction, including the generation of M2 TAMs, MDSCs, and the effect of IL-6 and IL-17 on the
stemness and suppressive (e.g., PD-L1 expression) properties of CSCs [94,99,116]. Many of these effects
could be reversed by inhibition of STAT3, rendering this molecule an attractive therapeutic target to
block CSCs-associated tumor immune evasion [171]. For example, inhibitor OPB-51602 is showing
promising effects against non-small cell lung carcinoma [172], and the STAT3 inhibitor napabucasin
was shown to reduce both expression of stemness-related genes and sphere formation by glioblastoma
cells [173].
Furthermore, the SIRPα ligand CD47 is overexpressed by CSCs, and could represents another
possible target for therapy [70]. Several studies showed an increased phagocytosis of CSCs by
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macrophages upon blocking of CD47, and multiple CD47 inhibitors are being tested in ongoing clinical
trials [73,174].
Additionally, CSCs were shown to express increased levels of the immune checkpoint PD-L1,
which correlated with EMT [175]. In turn, in gastric cancer, PD-L1 binding to PD-1 enhanced
CSCs proliferation [176]. Gupta et al. reported that PD-L1 knock-down in B16 murine melanoma
cells significantly reduced the CSC population [177]. Together, these studies suggest that using
immunotherapeutic agents, such as the checkpoint blockade inhibitors, may be an effective way of
targeting CSCs.
TGF-β, secreted by Tregs, M2 macrophages or CSCs themselves, is a crucial mediator of
immunosuppression that can be targeted by neutralizing antibodies [178]. The inhibition of the
pro-angiogenic VEGF has also been proven beneficial as combination therapy in several tumors,
and could be used to block the CSC-mediated angiogenesis [179].
Finally, CSCs might be eliminated by using specific immunotherapeutic approaches, such as
drug-conjugated monoclonal antibodies, DC-based therapeutic vaccines, and chimeric antigen receptor-
or T cell receptor-engineered T cells (CAR T-cells), targeting antigens that are characteristically
expressed by CSCs [180–184]. While these approaches may help to design efficient therapies for
eradication of CSCs, to this end it will be necessary to improve our knowledge of the biology of CSCs,
and the cellular interactions they establish within the TME.
4. Conclusions
CSCs and immune cells are the key players in tumor onset, progression and metastasis formation,
shaping the primary tumor microenvironment, as well as premetastatic sites, through triangular and
reciprocal interactions with stroma cells. The biology of CSCs, and the complexity of their intricated
microenvironmental cross-talk, have not yet been completely clarified. In particular, understanding of
the mechanisms that guide the plasticity and phenotype of CSCs (i.e., immunogenicity, proliferation
rate, differentiation, migration, etc.) during neoplastic evolution, as well as the identification of CSCs’
specific markers, represent the major limitations for CSC-targeted anticancer therapies, which aim at
the complete eradication of the tumor and the effective prevention of relapses. Additional contributions
to an effective therapeutic targeting of CSCs will likely come from a better understanding of how
inflammatory circuits and immune cells sculpt CSCs functions, thus influencing their awakening
and entry into the cell cycle, and promoting disease recurrence, as well as resistance and survival to
anticancer therapies.
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ADCC antibody-dependent cellular cytotoxicity
APC Antigen-presenting cell
APM Antigen-processing machinery
BCL B cell lymphoma
BMDC Bone marrow-derived cell
CAF Cancer-associated fibroblast
CCL Chemokine (C-C motif) ligand
CSF1 Colony-stimulating factor 1
CXCL Chemokine (C-X-C motif) ligand
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CXCR Chemokine (C-X-C motif) receptor
CRC Colorectal cancer
CSC Cancer stem cell
CTL Cytotoxic T cell
DC Dendritic cells
EGF Epidermal growth factor
EMT Epithelial-to-mesenchymal transition
GM-CSF Granulocyte-macrophage colony-stimulating factor
G-MDSC Granulocytic myeloid-derived suppressor cell
HCC Hepatocellular carcinoma
HLA Human leukocyte antigen
HNSCC Head and neck squamous cell carcinoma
IFNγ Interferon gamma
IL Interleukin
iNOS induced Nitric Oxide synthase
MDSC Myeloid-derived suppressor cell
M-MDSC Monocytic myeloid-derived suppressor cell
MHC Major histocompatibility complex
NET Neutrophil extracellular trap
NK Natural Killer cells
NKG2D/A Natural killer group 2 member D/A
NKT Natural killer T cell
NO Nitric oxide
NSCLC Non-small cell lung cancer
PBMC peripheral blood mononuclear cell
PC Pancreatic cancer
PDAC Pancreatic ductal adenocarcinoma
PGE2 Prostaglandin E2
SIRP Signal regulatory protein
SPARC Secreted protein acidic and rich in cysteine




TGF Transforming growth factor
Th T helper cell
Treg Regulatory T cell
TME Tumor microenvironment
TNFα Tumor necrosis factor alpha
TRAIL TNF-related apoptosis-inducing ligand
VEGF Vascular endothelial growth factor
XCL1 X-C Motif Chemokine Ligand 1
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